{
    "root": "11095ca8-ef1a-4f4e-a044-ac6d2186ee1a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "IMPAVIDO",
    "value": "20250319",
    "ingredients": [
        {
            "name": "MILTEFOSINE",
            "code": "53EY29W7EC"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "IMPAVIDO (miltefosine) capsules are indicated in adults and pediatric patients 12 years of age and older weighing greater than or equal to 30 kg (66 lbs) for the treatment of:\n                  \n                     \n                        •Visceral leishmaniasis caused by Leishmania donovani [see Clinical Trials (14.1)]. \n                     \n                        •Cutaneous leishmaniasis caused by Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis [see Clinical Trials (14.2)]. \n                     \n                        •Mucosal leishmaniasis caused by Leishmania braziliensis [see Clinical Trials (14.3)].\n                  \n                  \n                     Limitations of Use:\n                     \n                  \n                  \n                     \n                        •\n                        Leishmania species studied in clinical trials evaluating IMPAVIDO were based on epidemiologic data [see Clinical Trials (14.1, 14.2)]. \n                     \n                        •There may be geographic variation in clinical response of the same Leishmania species to IMPAVIDO [see Clinical Trials (14.1, 14.2)]. \n                     \n                        •The efficacy of IMPAVIDO in the treatment of other Leishmania species has not been evaluated.",
    "contraindications": "Verify pregnancy status prior to initiating IMPAVIDO in females of reproductive potential [see Use in Specific Populations, (8.3)].\n                  \n                  The treatment duration is 28 consecutive days. Administer with food to ameliorate gastrointestinal adverse reactions.\n                  \n                     Table 1: IMPAVIDO Dosage\n                     \n                     \n                     \n                        \n                           \n                              Weight\n                           \n                           \n                              Dosage and Administration\n                           \n                        \n                        \n                           \n                              30 kg to 44 kg\n                           \n                           \n                              One 50 mg capsule twice daily with food (breakfast and dinner) \n                           \n                        \n                        \n                           \n                              45 kg or greater \n                           \n                           \n                              One 50 mg capsule three times daily with food (breakfast, lunch, and dinner)",
    "warningsAndPrecautions": "Each IMPAVIDO capsule contains 50 mg miltefosine in an opaque, red, hard gelatin capsule. IMPAVIDO capsules are supplied in a folded peel/push-through child-resistant blister card.  Each blister card contains 14 capsules. Each carton contains two blister cards (NDC 69051-300-01).\n                  Store at 20-25 °C (68-77 °F); excursions permitted to 15-30 °C (59-86 °F). [See USP Controlled Room Temperature].  Protect from moisture. \n                  Dispense only in the original carton.",
    "adverseReactions": "• Pregnancy ( 4.1 , 5.1 , 8.1 ). • Sjögren-Larsson-Syndrome ( 4.2 , 12.3 ). • Hypersensitivity to miltefosine or any of its excipients ( 4.3 )."
}